ArcelorMittal SA vs Zoetis Inc — how do they compare? ArcelorMittal SA trades at $74.2 (market cap $55.96B), while Zoetis Inc trades at $75.11 (market cap $30.92B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| MT | ZTS | |
|---|---|---|
Market Cap | $55.96B | $30.92B |
Sector | Basic Materials | Health |
52-Week High | $75.35 | $156.76 |
52-Week Low | $32.44 | $71.91 |
Enterprise Value | $65.53B | $38.49B |
Dividend Yield | 0.81% | 2.83% |
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $73.29, up 0.1% with bullish technical signals from moving averages despite recent earnings miss. The company shows improving fundamentals with Q2 2026 revenue growth and strong cash flow generation of $4.8B from operations. Recent corporate developments include dividend payments and strategic partnerships with Microsoft, while analyst consensus remains positive with 50% buy ratings.
Outlook remains cautiously optimistic with European business recovery potential, though risks include cyclical steel demand volatility and elevated debt levels. The stock offers value with reasonable P/S (0.89) and P/B (1.01) ratios, but investors should monitor execution on second-half shipment guidance and margin pressures from input costs.
Zoetis (ZTS) trades at $72.66, down 5.92% amid a bearish technical signal and recent earnings pressure. The stock is near its 52-week low after Piper Sandler cut its price target to $80.00 on August 11, 2026. Despite strong profitability with a net margin of 27.69% and ROE of 64.91%, Q2 2026 revenue missed estimates, and the company reduced its 2026 outlook due to softer pet healthcare demand. Cash flow improved in 2025 with net cash flow of $325 million, but debt-to-asset ratio remains elevated at 46.14%.
The outlook is cautious with near-term headwinds in companion animal markets, but long-term fundamentals remain solid given the company's leading position in animal health. Risks include competitive pressures and a class action lawsuit. Analyst consensus is a Buy with a $95.00 price target, implying significant upside if execution improves.
Trailing returns across standard periods
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →